Tymińska Agata, Ozierański Krzysztof, Wawrzacz Marek, Balsam Paweł, Maciejewski Cezary, Kleszczewska Magdalena, Zawadzka Magdalena, Marchel Michał, Crespo-Leiro Maria G, Maggioni Aldo P, Drożdż Jarosław, Opolski Grzegorz, Grabowski Marcin, Kapłon-Cieślicka Agnieszka
1st Department of Cardiology, Medical University of Warsaw, Poland.
Complexo Hospitalario Universitario A Coruña (CHUAC)-CIBERCV, La Coruña, Spain.
Cardiol J. 2022 Aug 17;30(6):964-73. doi: 10.5603/CJ.a2022.0076.
Higher resting heart rate (HR) in patients with heart failure (HF) and sinus rhythm (SR) is associated with increased mortality. In patients hospitalized for HF, the aim herein, was to assess the use and dosage of guideline-recommended HR lowering medications, HR control at discharge and predictors of HR control.
In the present study, were Polish participants of the European Society of Cardiology HF Long-Term (ESC-HF-LT) Registry. Those selected were hospitalized for HF, with reduced ejection fraction (HFrEF) and SR at discharge (n = 236). The patients were divided in two groups ( < 70 and ≥ 70 bpm). Logistic regression was used to identify the predictors of HR ≥ 70 bpm.
Of patients with HFrEF and SR, 59% had HR ≥ 70 bpm at hospital discharge. At discharge, 96% and only 0.5% of the patients with HFrEF and SR received beta-blocker and ivabradine, respectively. In the HF groups < 70 and ≥ 70 bpm, only 11% and 4% of patients received beta-blocker target doses, respectively. There was no difference in the use of other guideline-recommended medications. Age, New York Heart Association class, HR on admission and lack of HR lowering medications were predictors of discharge HR ≥ 70 bpm.
Heart rate control after hospitalization for HFrEF is unsatisfactory, which may be attributed to suboptimal doses of beta-blockers, and negligence in use other HR lowering drugs (including ivabradine).
心力衰竭(HF)且窦性心律(SR)患者的静息心率(HR)较高与死亡率增加相关。对于因HF住院的患者,本研究旨在评估指南推荐的降低心率药物的使用情况和剂量、出院时的心率控制情况以及心率控制的预测因素。
在本研究中,选取了欧洲心脏病学会HF长期(ESC-HF-LT)注册研究的波兰参与者。入选者因HF住院,出院时射血分数降低(HFrEF)且为SR(n = 236)。患者被分为两组(<70和≥70次/分钟)。采用逻辑回归分析来确定HR≥70次/分钟的预测因素。
在HFrEF和SR患者中,59%在出院时HR≥70次/分钟。出院时,HFrEF和SR患者中分别有96%和仅0.5%接受了β受体阻滞剂和伊伐布雷定治疗。在HR<70次/分钟和≥70次/分钟的HF组中,分别只有11%和4%的患者接受了β受体阻滞剂目标剂量治疗。在使用其他指南推荐药物方面没有差异。年龄、纽约心脏协会分级、入院时的心率以及未使用降低心率药物是出院时HR≥70次/分钟的预测因素。
HFrEF住院后的心率控制不理想,这可能归因于β受体阻滞剂剂量未达最佳以及在使用其他降低心率药物(包括伊伐布雷定)方面的疏忽。